Substituted tetrahydropyrans as CCR2 modulators
Compounds are provided that are modulators of the CCR2 receptor. The compounds have the general formula (I): and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activation of CCR2 receptors.
1. A method for treating a mammal suffering from a disease or disorder selected from the group consisting of diabetic nephropathy, nonalcoholic statohepatitis, and pancreatic cancer, comprising administering to the mammal an effective amount of a compound selected from the group consisting of
or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein said compound has the formula
or a pharmaceutically acceptable salt thereof.
3. The method of claim 2 , wherein said disease or disorder is diabetic nephropathy.
4. The method of claim 2 , wherein said disease or disorder is nonalcoholic statohepatitis.
5. The method of claim 2 , wherein said disease or disorder is pancreatic cancer.
6. The method of claim 1 , wherein said compound has the formula
or a pharmaceutically acceptable salt thereof.
7. The method of claim 6 , wherein said disease or disorder is diabetic nephropathy.
8. The method of claim 6 , wherein said disease or disorder is nonalcoholic statohepatitis.
9. The method of claim 6 , wherein said disease or disorder is pancreatic cancer.
10. The method of claim 1 , wherein said compound has the formula
or a pharmaceutically acceptable salt thereof.
11. The method of claim 10 , wherein said disease or disorder is diabetic nephropathy.
12. The method of claim 10 , wherein said disease or disorder is nonalcoholic statohepatitis.
13. The method of claim 10 , wherein said disease or disorder is pancreatic cancer.